# The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

> **NCT00482664** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 84 (estimated)

## Conditions studied

- Sexual Dysfunction, Physiological

## Interventions

- **DRUG:** CP-866,087
- **DRUG:** CP-866,087
- **DRUG:** CP-866,087
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00482664
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-09
- **Final completion:** 2008-10
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2010-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482664, "The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00482664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*